Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 10/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13141385 | 0.93 | TK2 (0.52) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3078294 | 0.92 | TK2 (0.51) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL14292729 | 0.92 | TK2 (0.51) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3078295 | 0.92 | TK2 (0.51) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3082760 | 0.89 | TK2 (0.64) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL13141383 | 0.85 | TK2 (0.43) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3082518 | 0.83 | TK1 (0.48) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL17146890 | 0.81 | TK1 (0.60) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3078268 | 0.81 | TK1 (0.46) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3084627 | 0.79 | TK1 (0.57) | TK2CYP1A2CYP3A4TSHRTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |